相似文献
1
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.
Adv Drug Deliv Rev. 2008 Sep;60(12):1421-34. doi: 10.1016/j.addr.2008.04.012. Epub 2008 Apr 24.
2
Theoretic criteria for antibody penetration into solid tumors and micrometastases.
J Nucl Med. 2007 Jun;48(6):995-9. doi: 10.2967/jnumed.106.037069. Epub 2007 May 15.
3
Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism.
Microvasc Res. 1991 Jan;41(1):5-23. doi: 10.1016/0026-2862(91)90003-t.
4
Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention.
Cancer Res. 2003 Mar 15;63(6):1288-96.
5
Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.
Cancer Res. 2011 Mar 15;71(6):2250-9. doi: 10.1158/0008-5472.CAN-10-2277.
6
Factors determining antibody distribution in tumors.
Trends Pharmacol Sci. 2008 Feb;29(2):57-61. doi: 10.1016/j.tips.2007.11.004. Epub 2008 Jan 7.
7
The macroscopic and microscopic pharmacology of monoclonal antibodies.
Int J Immunopharmacol. 1992 Apr;14(3):457-63. doi: 10.1016/0192-0561(92)90176-l.
8
Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids.
Cancer Res. 2008 May 1;68(9):3334-41. doi: 10.1158/0008-5472.CAN-07-3018.
9
10
A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors.
Cancer Res. 1992 Nov 1;52(21):5954-62.
引用本文的文献
1
The molecular blueprint of targeted radionuclide therapy.
Nat Rev Clin Oncol. 2025 Sep 9. doi: 10.1038/s41571-025-01069-z.
2
A Complementarity-Based Approach to De Novo Binder Design.
Adv Sci (Weinh). 2025 Sep;12(33):e02015. doi: 10.1002/advs.202502015. Epub 2025 Jul 21.
3
Advancements in non-invasive visualization of the immune checkpoint TIGIT: a systematic review.
Eur J Nucl Med Mol Imaging. 2025 Jul 15. doi: 10.1007/s00259-025-07439-0.
4
Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapy.
Nat Biomed Eng. 2025 Jun 26. doi: 10.1038/s41551-025-01432-6.
5
Hiding in Plain Sight: Cell Biomimicry for Improving Hematological Cancer Outcomes.
Nanomaterials (Basel). 2025 May 15;15(10):739. doi: 10.3390/nano15100739.
6
HER2 expression in different cell lines at different inoculation sites assessed by [Mn]Mn-DOTAGA(anhydride)-trastuzumab.
Pathol Oncol Res. 2025 Apr 29;31:1611999. doi: 10.3389/pore.2025.1611999. eCollection 2025.
7
Investigations of Influence of Antibody Binding Kinetics on Tumor Distribution and Anti-Tumor Efficacy.
AAPS J. 2025 May 9;27(4):91. doi: 10.1208/s12248-025-01076-z.
8
The physiological limits of bispecific monoclonal antibody tissue targeting specificity.
MAbs. 2025 Dec;17(1):2492236. doi: 10.1080/19420862.2025.2492236. Epub 2025 Apr 13.
9
Antibody-drug conjugates in breast cancer: current evidence and future directions.
Exp Hematol Oncol. 2025 Mar 20;14(1):41. doi: 10.1186/s40164-025-00632-9.
10
Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life.
PNAS Nexus. 2025 Feb 11;4(2):pgaf042. doi: 10.1093/pnasnexus/pgaf042. eCollection 2025 Feb.
本文引用的文献
1
Factors determining antibody distribution in tumors.
Trends Pharmacol Sci. 2008 Feb;29(2):57-61. doi: 10.1016/j.tips.2007.11.004. Epub 2008 Jan 7.
2
Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.
J Immunol. 2007 Sep 1;179(5):2815-23. doi: 10.4049/jimmunol.179.5.2815.
3
Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
J Pharmacokinet Pharmacodyn. 2007 Oct;34(5):687-709. doi: 10.1007/s10928-007-9065-1. Epub 2007 Jul 18.
4
Theoretic criteria for antibody penetration into solid tumors and micrometastases.
J Nucl Med. 2007 Jun;48(6):995-9. doi: 10.2967/jnumed.106.037069. Epub 2007 May 15.
5
Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.
Cancer Res. 2007 Mar 15;67(6):2729-35. doi: 10.1158/0008-5472.CAN-06-4102.
6
Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
J Biol Chem. 2007 Apr 27;282(17):12650-60. doi: 10.1074/jbc.M700820200. Epub 2007 Mar 8.
7
Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.
Cancer Res. 2007 Jan 15;67(2):718-26. doi: 10.1158/0008-5472.CAN-06-0454.
8
Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent.
Cancer Res. 2007 Jan 1;67(1):254-61. doi: 10.1158/0008-5472.CAN-06-2531.
9
Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness.
Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18721-6. doi: 10.1073/pnas.0609025103. Epub 2006 Nov 27.
10
Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis.
J Chemother. 2006 Oct;18(5):532-7. doi: 10.1179/joc.2006.18.5.532.
Zotero 插件